For the Sake of Public Safety FDA & NIH Must Be Detatched from Drug Industry Tue, 21 Dec 2004 Daily front page reports about lethal drug effects leave no doubt that we are in the midst of a major health safety and credibility crisis, largely due to a drug development…
FDA’s Lethal Weakness Requires More than Committees Sun, 7 Nov 2004 Bloomberg News reports that New York State Attorney General Eliot Spitzer requested information from Pfizer about the promotion of some of its drugs for unapproved uses – the recalled diabetes drug, Rezulin and the antidepressant, Zoloft were named. In…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…
TeenScreen: Who Pays for Treatment and Drugs?? Sun, 29 May 2005 In her latest examination of the President’s Commission on Mental Health recommendation for universal mental health screening, Evelyn Pringle focuses on the $$$ it costs and on how screening, followed by prescribing psychotropic drugs, is bankrupting of public health…
Drugmakers Go Furthest to Sway Congress: 1,274 Lobbyists – USA Today Tue, 26 Apr 2005 USA Today provides a glimpse into the way the pharmaceutical industry controls health care policy by buying influence at the highest level of government, and underwriting professional and lay healthcare organizations whose spokespersons parrot industry’s…
10 of 32 FDA Vioxx Panelists Had Industry Ties_NYT / Cozy NIH Review “Clears” NIH Industry Ties_WashPost Fri, 25 Feb 2005 The latest example of the corrupting influence of the pharmaceutical industry on health care policy is the composition of FDA’s advisory panel that last week endorsed the marketing of…
Practice Guidelines: Can We Trustthe Evidence in Evidence-Based Medicine? Sun, 25 Sep 2005 “Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?” is an article by Dr. John Abramson* (Harvard) and Dr. Barbara Starfeld (Distinguished Professor, Johns Hopkins), published in the Journal of the American Board…
Jayson Blair, reporter fired from NY Times, helped PhRMA scare consumers . . . Sun, 23 Oct 2005 Below Peter Rost, V-P of Marketing at Pfizer who has turned whistleblower on the pharmaceutical industry sent us the most amazing example of this industry’s loathsome underhanded tactics aimed at scaring the…
Prescriptions for antidepressant declined 10% Thu, 13 May 2004 The controversy over the safety of antidepressant drugs is broadening. The Newark Star Ledger reports a drop in antidepressant prescriptions since the Feb 2 FDA advisory committee meeting. Disclosure of long concealed evidence about the severe adverse drug effects–as well as…
Consumers Union launches “Prescription for Change” drug information Campaign Mon, 13 Dec 2004 The Alliance for Human Research Protection applauds Consumers Union for joining and amplifying our efforts to promote open access and full disclosure of research information affecting the health and welfare of consumers young and old. Specifically, Consumers…
FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle Mon, 29 Nov 2004 The Food and Drug Administration is the epicenter of a collision between medical officers in the drug safety office and senior officials in managerial positions whose focus is on facilitating new drug approvals. Officials at the…
FDA Alert: Effexor warnings added for neonatal adverse effects and suicidality risk Tue, 29 Jun 2004 On June 28, the FDA and Wyeth issued a new MedWatch drug Alert to healthcare professionals: “Neonates exposed to Effexor, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late…
